|
Name |
Aspergillussanone I
|
Molecular Formula | C38H50O8 | |
IUPAC Name* |
2,4,6,9-tetrahydroxy-5,7-dimethyl-2-[3,7,11-trimethyl-13-(2,2,5,5-tetramethyl-1,3-dioxolan-4-yl)trideca-2,6,10-trienyl]phenalene-1,3-dione
|
|
SMILES |
CC(=CCCC(C)=CCC1(O)C(=O)c2c(O)cc(C)c3c(O)c(C)c(O)c(c23)C1=O)CCC=C(C)CCC1OC(C)(C)OC1(C)C
|
|
InChI |
InChI=1S/C38H50O8/c1-21(12-10-14-22(2)16-17-27-36(6,7)46-37(8,9)45-27)13-11-15-23(3)18-19-38(44)34(42)29-26(39)20-24(4)28-30(29)31(35(38)43)33(41)25(5)32(28)40/h13-14,18,20,27,39-41,44H,10-12,15-17,19H2,1-9H3/b21-13+,22-14+,23-18+/t27?,38-/m0/s1
|
|
InChIKey |
WQVQGYAICGPPAB-NNLMPRKCSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 634.81 | ALogp: | 8.2 |
HBD: | 4 | HBA: | 8 |
Rotatable Bonds: | 11 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 133.5 | Aromatic Rings: | 4 |
Heavy Atoms: | 46 | QED Weighted: | 0.136 |
Caco-2 Permeability: | -4.713 | MDCK Permeability: | 0.00001310 |
Pgp-inhibitor: | 0.987 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.044 | 20% Bioavailability (F20%): | 0.973 |
30% Bioavailability (F30%): | 0.042 |
Blood-Brain-Barrier Penetration (BBB): | 0.007 | Plasma Protein Binding (PPB): | 96.83% |
Volume Distribution (VD): | 2.224 | Fu: | 3.18% |
CYP1A2-inhibitor: | 0.088 | CYP1A2-substrate: | 0.234 |
CYP2C19-inhibitor: | 0.727 | CYP2C19-substrate: | 0.429 |
CYP2C9-inhibitor: | 0.903 | CYP2C9-substrate: | 0.91 |
CYP2D6-inhibitor: | 0.485 | CYP2D6-substrate: | 0.137 |
CYP3A4-inhibitor: | 0.28 | CYP3A4-substrate: | 0.473 |
Clearance (CL): | 2.355 | Half-life (T1/2): | 0.01 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.85 |
Drug-inuced Liver Injury (DILI): | 0.926 | AMES Toxicity: | 0.508 |
Rat Oral Acute Toxicity: | 0.064 | Maximum Recommended Daily Dose: | 0.402 |
Skin Sensitization: | 0.15 | Carcinogencity: | 0.959 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.386 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003494 | 0.674 | D03VFL | 0.305 | ||||
ENC003114 | 0.644 | D09XWD | 0.297 | ||||
ENC003842 | 0.635 | D05XQE | 0.271 | ||||
ENC003496 | 0.635 | D0WY9N | 0.256 | ||||
ENC005337 | 0.631 | D0FX2Q | 0.249 | ||||
ENC005338 | 0.630 | D0Q0PR | 0.235 | ||||
ENC005339 | 0.611 | D01ZUA | 0.233 | ||||
ENC005340 | 0.596 | D0G3DL | 0.216 | ||||
ENC003495 | 0.576 | D04ITO | 0.215 | ||||
ENC004068 | 0.383 | D05CHI | 0.210 |